Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4A
|
pubmed:dateCreated |
1992-6-9
|
pubmed:abstractText |
A total of 63 adult patients with uncomplicated acute pyelonephritis were enrolled in a multicenter, randomized comparison of lomefloxacin (400 mg orally once daily for 14 days) and trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days). Study participants were predominantly female (70% in the lomefloxacin group and 80% in the TMP/SMX group). Escherichia coli was isolated from pretreatment urine cultures in 87.5% of the lomefloxacin group and 80.0% of the TMP/SMX group. Baseline pathogens were eradicated in 100% of evaluable patients in the lomefloxacin group 5-9 days after the end of therapy and in 88.9% of patients in the TMP/SMX group (p = 0.05). The clinical cure rate 5-9 days after therapy with lomefloxacin was 65.0% and for TMP/SMX was 68.4%. At the 4-6 week follow-up in the lomefloxacin group, nine pathogens remained eradicated, one E. coli was isolated, and the results for 14 pathogens were unknown or unevaluable. In the TMP/SMX group, 12 pathogens remained eradicated, three E. coli and one Group D Streptococcus were isolated, and the results for nine pathogens were unknown or unevaluable. Both treatment regimens were well tolerated; adverse events occurred in 12% of patients in the lomefloxacin group and in 17% in the TMP/SMX group. Events considered by the investigators to be probably related to treatment occurred in three patients in each group. In conclusion, once-daily lomefloxacin (400 mg) was a well tolerated and effective alternative to twice-daily TMP/SMX (160/800 mg) for the treatment of adults with uncomplicated acute pyelonephritis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Trimethoprim-Sulfamethoxazole...,
http://linkedlifedata.com/resource/pubmed/chemical/lomefloxacin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0002-9343
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
6
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
87S-90S
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1316078-Acute Disease,
pubmed-meshheading:1316078-Adolescent,
pubmed-meshheading:1316078-Adult,
pubmed-meshheading:1316078-Aged,
pubmed-meshheading:1316078-Aged, 80 and over,
pubmed-meshheading:1316078-Anti-Infective Agents,
pubmed-meshheading:1316078-Escherichia coli Infections,
pubmed-meshheading:1316078-Female,
pubmed-meshheading:1316078-Fluoroquinolones,
pubmed-meshheading:1316078-Humans,
pubmed-meshheading:1316078-Male,
pubmed-meshheading:1316078-Middle Aged,
pubmed-meshheading:1316078-Pyelonephritis,
pubmed-meshheading:1316078-Quinolones,
pubmed-meshheading:1316078-Treatment Outcome,
pubmed-meshheading:1316078-Trimethoprim-Sulfamethoxazole Combination
|
pubmed:year |
1992
|
pubmed:articleTitle |
A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis.
|
pubmed:affiliation |
Service des Maladies Infectieuses, Centre Hospitalier de Tourcoing, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|